A 3-month course of colchicine significantly reduced early atrial fibrillation recurrence after pulmonary vein isolation compared to placebo (16% vs 33.5%; OR 0.38, 95% CI 0.18-0.80).
RCT (n=161)
randomized
Does colchicine reduce early atrial fibrillation recurrence in patients with paroxysmal AF after pulmonary vein isolation?
A 3-month course of colchicine significantly reduces early atrial fibrillation recurrence after pulmonary vein isolation, an effect associated with decreased inflammatory mediators.
Effect estimate: OR 0.38 (95% CI 0.18 to 0.80)
Absolute Event Rate: 16% vs 33.5%
OBJECTIVES: The purpose of the present study was to test the potential of colchicine, an agent with potent anti-inflammatory action, to reduce atrial fibrillation (AF) recurrence after pulmonary vein isolation in patients with paroxysmal AF. BACKGROUND: Proinflammatory processes induced by AF ablation therapy have been implicated in postablation arrhythmia recurrence. METHODS: Patients with paroxysmal AF who received radiofrequency ablation treatment were randomized to a 3-month course of colchicine 0.5 mg twice daily or placebo. C-reactive protein (CRP) and interleukin (IL)-6 levels were measured on day 1 and on day 4 of treatment. RESULTS: In the 3-month follow-up, recurrence of AF was observed in 27 (33.5%) of 80 patients of the placebo group versus 13 (16%) of 81 patients who received colchicine (odds ratio: 0.38, 95% confidence interval: 0.18 to 0.80). Gastrointestinal side-effects were the most common symptom among patients receiving active treatment. Diarrhea was reported in 7 patients in the colchicine group (8.6%) versus 1 in the placebo group (1.3%, p = 0.03). Colchicine led to higher reductions in CRP and IL-6 levels: the median difference of CRP and IL-6 levels between days 4 and 1 was -0.46 mg/l (interquartile range: -0.78 to 0.08 mg/l) and -0.10 mg/l (-0.30 to 0.10 pg/ml), respectively, in the placebo group versus -1.18 mg/l (-2.35 to -0.46 mg/l) and -0.50 pg/ml (-1.15 to -0.10 pg/ml) in the colchicine group (p < 0.01 for both comparisons). CONCLUSIONS: Colchicine is an effective and safe treatment for prevention of early AF recurrences after pulmonary vein isolation in the absence of antiarrhythmic drug treatment. This effect seems to be associated strongly with a significant decrease in inflammatory mediators, including IL-6 and CRP.
Deftereos et al. (Mon,) conducted a rct in paroxysmal atrial fibrillation (n=161). colchicine vs. placebo was evaluated on recurrence of AF in the 3-month follow-up (OR 0.38, 95% CI 0.18 to 0.80). A 3-month course of colchicine significantly reduced early atrial fibrillation recurrence after pulmonary vein isolation compared to placebo (16% vs 33.5%; OR 0.38, 95% CI 0.18-0.80).